Skip to main content
. 2017 Aug 3;7(8):e017406. doi: 10.1136/bmjopen-2017-017406

Table 2.

Frequency of antipsychotic drugs prescribed in the ID and non-ID cohorts

Antipsychotic drug ID cohort Non-ID cohort
Number Percentage Average daily dose, mg Median treatment duration, years Number Percentage Average daily dose, mg Median treatment duration, years
Risperidone 4013 28.5 1.9 1.81 7426 14.7 2.2 0.47
Olanzapine 2086 14.8 8.2 1.62 10 246 20.3 8.5 0.67
Chlorpromazine 1770 12.6 78.5 1.12 5274 10.5 64.8 0.20
Quetiapine 1295 9.2 154.1 0.93 7693 15.2 152.6 0.72
Haloperidol 1231 8.7 4.9 0.68 3755 7.5 3.2 0.14
Thioridazine 838 6.0 77.9 0.82 2672 5.3 49.8 0.20
Aripiprazole 661 4.7 10.5 0.74 2638 5.2 11.8 0.54
Trifluoperazine 456 3.2 6.5 1.06 3403 6.8 4.5 0.19
Zuclopenthixol 429 3.1 18.7 2.17 340 0.7 20.0 0.45
Amisulpride 327 2.3 295.0 0.94 1687 3.4 290.3 0.73
Promazine 276 2.0 58.4 0.33 1688 3.4 58.6 0.16
Sulpiride 276 2.0 437.8 1.97 1199 2.4 435.6 0.79
Other* 980 7.0 5230 10.4

*Other antipsychotic drugs prescribed to <1% of ID cohort each.

ID, intellectual disability.